<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 6. Effect of Other Drugs on Voriconazole Pharmacokinetics [see Clinical Pharmacology (<linkhtml href="#i4i_section_id_d037e54f-2fc7-4342-875d-561d6da2af9d">12.3</linkhtml>)] </caption>
<col width="34%"></col>
<col width="35%"></col>
<col width="32%"></col>
<tbody>
<tr>
<td stylecode="Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Drug/Drug Class </content>
<br/>
<content stylecode="bold">(Mechanism of Interaction by the Drug) </content>
</paragraph>
</td>
<td stylecode="Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Voriconazole Plasma Exposure </content>
<br/>
<content stylecode="bold">(C<sub>max</sub> and AUCτ after 200 mg q12h) </content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Recommendations for Voriconazole Dosage Adjustment/Comments </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Rifampin* and Rifabutin* <br/>(CYP450 Induction) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Significantly Reduced </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Efavirenz (400 mg q 24h)** </paragraph>
<paragraph>(CYP450 Induction) </paragraph>
<paragraph>Efavirenz (300 mg q 24h) **</paragraph>
<paragraph>(CYP450 Induction)</paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Significantly Reduced </paragraph>
<paragraph>Slight decrease in AUC<sub>t</sub>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
<paragraph>When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule ">
<paragraph>High-dose Ritonavir (400 mg q12h)** (CYP450 Induction)</paragraph>
</td>
<td stylecode="Lrule ">
<paragraph>Significantly Reduced</paragraph>
</td>
<td stylecode="Rrule Lrule ">
<paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Low-dose Ritonavir (100 mg q12h)** (CYP450 Induction) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Reduced</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Carbamazepine <br/>(CYP450 Induction) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Long Acting Barbiturates <br/>(CYP450 Induction) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Phenytoin*<br/>(CYP450 Induction) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Significantly Reduced </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV q12h or from 200 mg to 400 mg orally q12h (100 mg to 200 mg orally q12h in patients weighing less than 40 kg) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>St. John’s Wort <br/>(CYP450 inducer; P-gp inducer) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Significantly Reduced </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Oral Contraceptives** <br/>containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Increased </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Fluconazole** (CYP2C9, CYP2C19 and CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>Significantly Increased </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is started within 24 h after the last dose of fluconazole. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule ">
<paragraph>Other HIV Protease Inhibitors <br/>(CYP3A4 Inhibition) </paragraph>
</td>
<td stylecode="Lrule Botrule ">
<paragraph>
<content stylecode="italics">In Vivo</content> Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure <br/>
</paragraph>
<paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure) </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir </paragraph>
<paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule ">
<paragraph>Other NNRTIs*** </paragraph>
<paragraph>(CYP3A4 Inhibition or CYP450 Induction) </paragraph>
</td>
<td stylecode="Lrule ">
<paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)</paragraph>
</td>
<td stylecode="Rrule Lrule ">
<paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule Lrule "></td>
<td stylecode="Botrule Lrule ">
<paragraph>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure) </paragraph>
</td>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>Careful assessment of voriconazole effectiveness </paragraph>
</td>
</tr>
</tbody>
</table>